The Filler For Flat Cheeks Gets FDA Approval

The Filler For Flat Cheeks Gets FDA Approval featured image

When it comes to fixing flat cheeks and smile lines, a new Restalyne filler that just received FDA-approval is the one to know about.

With an 88.7-percent improvement rate in clinical trials, Galderma announced today that its injectable gel Restylane Lyft has received approval by the FDA to be used for cheek augmentation.

This is great news for patients who want fillers that have been vetted by a trusted source. “Consumers are looking for safe, high-quality products that can deliver natural-looking results,” says Kelly Huang, vice president and general manager of Galderma’s Aesthetic and Corrective Business Unit in the U.S., according to the company’s press release.

Once treated with this injectable gel, you can expect to see improvement with the appearance of your midface immediatel. Additionally, 73 percent of patients reported improvement after 12 months. Reported side effects include bruising, redness, swelling, pain, headaches, tenderness and itching.

“Achieving natural-looking lift in the cheek area is one of the most common requests that I receive from my patients,” says Hunt Valley, MD, Robert Weiss, MD, and principal investigator of the clinical trial, according to the company’s press release. “The results of this clinical trial show that Restylane Lyft can provide an effective option for patients when they desire lift—not just volume_in their cheeks.”

Restylane Lyft is not the only FDA-approved product to join the Restylane family. Restylane was first FDA-approved to correct and smooth lines that are caused by smiles and lip augmentation. 

As with any cosmetic procedure, be sure to discuss with your board-certified medical professional to make sure this filler is right for you.

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.